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Introduction
Familial Mediterranean Fever (FMF) is the most com-
mon periodic fever syndrome, characterized by recurrent
fever and serositis attacks. It has been shown that there
might be an ongoing subclinical inflammation between
attacks. Adrenomedullin (ADM) is synthesized in
endothelium, and has been shown to have high levels in
patients with inflammation such as FMF. Colchicine is
the treatment of choice and given once or twice daily
depending on expert opinion.
Objectives
In this study, it was aimed to investigate ADM as a mar-
ker for inflammation in pediatric patients with FMF who
are using colchicine in different dosage schema.
Methods
Pediatric patients diagnosed with clinically and geneti-
cally confirmed FMF diagnosis were included in the
study. The Colchicine was started in one or two doses
randomly. The clinical and laboratory parameters were
assessed on six clinical visits made every two months.
After the third visit the dosing schema was changed to
twice or once depending on the schema at the beginning.
Results
A total of 37 patients were included in the study. Mean
age of patients was 7.78±2.00 years, mean age at disease
onset was 5.05 ± 3.04 years and mean age at diagnosis was
7.51 ± 2.66 years. Twenty patients received colchicine in
once daily dosage while 17 patients had in twice daily
dosage at the beginning of the study. There were 10
patients with heterozygote and 27 with homozygote
MEFV mutations. After the treatment was started all
patients demonstrated improvement in clinical and labora-
tory findings such as erythrocyte sedimentation rate and
C-reactive protein. However, ADM levels did not show
any correlation with ESR and CRP levels. Mean ADM
levels in six consequtive visits were as follows, first
322.19±161.92 ng/L; second 330.50±189.63 ng/L; third
339.54±168.03 ng/L; forth 378.11±177.63 ng/L; fifth
328.91±172.30 ng/L and sixth 326.25±165.87 ng/L. ADM
levels were similar in all visits (p=0.954) and did not
show any difference between the first and second three
visits i.e. before and after changing the dosage schema
(p=0.593).
Conclusion
The results indicated that patients using colchicine in
once or twice daily doses did not demonstrate any dif-
ference considering clinical and laboratory findings and
had similar effects in controlling disease manifestations.
ADM levels did not demonstrate any alterations in all
visits which may suggest the continuation of subclinical
inflammation in these patients.
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